ABF Ingredients (ABFI) has revealed a significant restructuring of its health and nutrition segment, consolidating three of its main businesses—ABbiotek Health, Fytexia, and Anzchem—into a single entity known as Biotexia.
This integration signals the conclusion of these businesses operating as separate brands, establishing a more cohesive partner in the global nutraceutical and functional food markets.
The merger’s purpose is to create a streamlined interface for clients increasingly seeking comprehensive, scientifically validated solutions instead of standalone components. By unifying these specialized areas, ABF Ingredients seeks to dissolve the previous separations between expertise in microbial fermentation, botanical extraction, and regional distribution.
“The creation of Biotexia is a logical step in our strategic evolution,” stated Laurent Hubert, CEO of Biotexia. “By bringing our teams together, we’re not just merging our portfolios; we are building a more integrated platform to enhance support for our clients’ innovation processes, extending from initial clinical research through to the final stages of product development.”
The new brand’s strategic focus lies within high-growth wellness areas, such as digestive health, immune function, metabolic processes, cognitive health, and women’s wellness. This merger is expected to expedite the commercialization of proprietary ingredients, like specialized propolis extracts and microbiome-modulating solutions, by combining research and development efforts.
“Our aim is to connect pharmaceutical-grade effectiveness with the shifting demands of the food and beverage industry,” Hubert further explained. “Modern consumers are pursuing health advantages that easily integrate into their routines, moving away from traditional pills towards functional options like powders, bars, and fortified beverages. Biotexia is now distinctly positioned to deliver the stable, clinically validated ingredients that enable these products.”
This comprehensive R&D approach is also aimed at simplifying the creation of robust clinical documentation, an increasingly vital aspect of complying with global regulatory standards. By centralizing operations in France, Spain, Italy, and the Netherlands, Biotexia plans to strengthen its international supply chain while aggressively expanding in the Asia-Pacific region.
The shift to the Biotexia brand is currently in progress across all global markets, with the company anticipating that the complete integration of its marketing and product lines will be finalized by mid-2026.
